• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Related Links
    • FAQ
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Iranian Journal of Pharmaceutical Research
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 18 (2019)
Volume Volume 17 (2018)
Volume Volume 16 (2017)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Special Issue
Issue Issue 1
Volume Volume 15 (2016)
Volume Volume 14 (2015)
Volume Volume 13 (2014)
Volume Volume 12 (2013)
Volume Volume 11 (2012)
Volume Volume 10 (2011)
Volume Volume 9 (2010)
Volume Volume 8 (2009)
Volume Volume 7 (2008)
Volume Volume 6 (2007)
Volume Volume 5 (2006)
Volume Volume 4 (2005)
Volume Volume 3 (2004)
Volume Volume 2 (2003)
Volume Volume 1 (2002)
Mortazavi, N., Esmaeilzadeh, H., Abbasinazari, M., Babaie, D., Alyasin, S., Nabavizadeh, H., Esmailzadeh, E. (2017). Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease. Iranian Journal of Pharmaceutical Research, 16(4), 1639-1647. doi: 10.22037/ijpr.2017.2141
Negar Mortazavi; Hossein Esmaeilzadeh; Mohammad Abbasinazari; Delara Babaie; Soheila Alyasin; Hesamodin Nabavizadeh; Elmira Esmailzadeh. "Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease". Iranian Journal of Pharmaceutical Research, 16, 4, 2017, 1639-1647. doi: 10.22037/ijpr.2017.2141
Mortazavi, N., Esmaeilzadeh, H., Abbasinazari, M., Babaie, D., Alyasin, S., Nabavizadeh, H., Esmailzadeh, E. (2017). 'Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease', Iranian Journal of Pharmaceutical Research, 16(4), pp. 1639-1647. doi: 10.22037/ijpr.2017.2141
Mortazavi, N., Esmaeilzadeh, H., Abbasinazari, M., Babaie, D., Alyasin, S., Nabavizadeh, H., Esmailzadeh, E. Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease. Iranian Journal of Pharmaceutical Research, 2017; 16(4): 1639-1647. doi: 10.22037/ijpr.2017.2141

Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease

Article 35, Volume 16, Issue 4, Autumn 2017, Page 1639-1647  XML PDF (466.17 K)
Document Type: Research article
DOI: 10.22037/ijpr.2017.2141
Authors
Negar Mortazavi1; Hossein Esmaeilzadeh2; Mohammad Abbasinazari email 1; Delara Babaie3; Soheila Alyasin4; Hesamodin Nabavizadeh4; Elmira Esmailzadeh5
1Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Allergy research center, Shiraz University of Medical Sciences, Shiraz
3Department of Allergy and Clinical Immunology, Mofid Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Allergy research center, Shiraz University of Medical Sciences, Shiraz, Iran
5Department of Internal Medicine, Division of Rheumatology, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract
This study aimed to investigate the efficacy and the underlining mechanism of aspirin
desensitization among patients with Aspirin Exacerbated Respiratory Disease (AERD). Thirtyeight
patients, who had undergone an aspirin challenge test and were diagnosed as having
AERD, were engaged in a double-blind randomized clinical trial. They were divided into two
groups—an active group of patients who went through aspirin desensitization, and the control
group, receiving placebo. Clinical symptoms and the quality of life of the patients—in addition
to the levels of interleukin 4 and 5 (IL4), (IL5)—were documented at the beginning of the study
and again after six months of aspirin desensitization. The quality of life of the patients was
significantly higher in the active group after six months (P = 0.001). Medication requirements
and symptom score were manifested to be significantly lower in the active group after six
months than at the beginning of the study (P = 0.005, 0.017 respectively). Forced expiratory
volume in the second one (FEV1) was, also, significantly higher in the active group after six
months of the study (P = 0.032). IL5 was found to be significantly lower in the active group
after six months (P = 0.019). However, no significant difference was observed in the levels
of IL4 between the two groups (P = 0.152). The study revealed that aspirin desensitization
can improve the quality of life of patients with AERD, lessen their symptoms and medication
requirements, lower their levels of IL5, and improve some pulmonary function tests such as
FEV1.
Keywords
AERD; Aspirin; Desensitization; Interleukin-5; Interleukin-4
Main Subjects
Pharmacotherapy (Clinical Pharmacy)
Statistics
Article View: 1,253
PDF Download: 8,079
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Statistics

Journal Management System. Designed by sinaweb.